Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-G21 pembrolizumab in Japanese pediatric solid tumors/lymphomas and adult Merkel cell carcinoma
jRCT2041250120Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in classical Hodgkin lymphoma (cHL), primary mediastinal large B-cell lymphoma (PMBCL), melanoma and 2 more (2 cohorts), sponsored by Merck & Co. Primary endpoints: Adverse events (Cohort 1), Pharmacokinetic parameters for pembrolizumab (Cohort 1) and 1 more. Started Jun 2026; status: recruiting.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)primary mediastinal large B-cell lymphoma (PMBCL)melanomaNonhematologic neoplasmsMerkel cell carcinoma (MCC)
Beyond the preview
Go deeper on jRCT2041250120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041250120.